23 May 2025
23 May 2025
Market analysts have called Vigil鈥檚 oral drug a "paradigm shifter" in Alzheimer鈥檚 disease treatment.
The decision is supported by positive data from the Phase III MATINEE and METREX trials.
An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea 8mg.
Dubbed a "big, beautiful bill" by the White House, observers warn that the legislation will profoundly impact Medicaid and Medicare programmes.
The partnership will include $105m upfront to Orionis, with the potential for further payments that could exceed $2bn.
The UK has demonstrated resilience with sustained YoY growth, signalling investor confidence in the region.
The collaboration aims to integrate the algorithms into routine eye examinations, facilitating diagnosis.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
